Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix

Dana, Rohitashwa; Spartacus, RK; Mutha, Shweta; Bhat, Prashanth

doi:10.4103/0253-7613.194863

Cited by 7 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we discovered that GADD45A interacts with genistein and cisplatin. Genistein has been implicated in antiepileptic effects [ 42 , 43 ], while cisplatin has been reported to induce seizures [ 44 , 45 ]. Therefore, the results of the PPI networks and drug–gene interaction further underscore the significant role of GADD45A in epilepsy therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of potential crucial genes and therapeutic targets for epilepsy

Wang,

Xie,

Jun

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background Epilepsy, a central neurological disorder, has a complex genetic architecture. There is some evidence suggesting that genetic factors play a role in both the occurrence of epilepsy and its treatment. However, the genetic determinants of epilepsy are largely unknown. This study aimed to identify potential therapeutic targets for epilepsy. Methods Differentially expressed genes (DEGs) were extracted from the expression profiles of GSE44031 and GSE1834. Gene co-expression analysis was used to confirm the regulatory relationship between newly discovered epilepsy candidate genes and known epilepsy genes. Expression quantitative trait loci analysis was conducted to determine if epilepsy risk single-nucleotide polymorphisms regulate DEGs’ expression in human brain tissue. Finally, protein–protein interaction analysis and drug–gene interaction analysis were performed to assess the role of DEGs in epilepsy treatment. Results The study found that the protein tyrosine phosphatase receptor-type O gene (PTPRO) and the growth arrest and DNA damage inducible alpha gene (GADD45A) were significantly upregulated in epileptic rats compared to controls in both datasets. Gene co-expression analysis revealed that PTPRO was co-expressed with RBP4, NDN, PAK3, FOXG1, IDS, and IDS, and GADD45A was co-expressed with LRRK2 in human brain tissue. Expression quantitative trait loci analysis suggested that epilepsy risk single-nucleotide polymorphisms could be responsible for the altered PTPRO and GADD45A expression in human brain tissue. Moreover, the protein encoded by GADD45A had a direct interaction with approved antiepileptic drug targets, and GADD45A interacts with genistein and cisplatin. Conclusions The results of this study highlight PTPRO and GADD45A as potential genes for the diagnosis and treatment of epilepsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of potential crucial genes and therapeutic targets for epilepsy

Wang,

Xie,

Jun

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…The neurotoxicity mostly affects the peripheral nervous system. It can be explained by the higher susceptibility of platinum drugs to access the dorsal root ganglia and peripheral nerves, in comparison to the central nervous system (CNS) [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Thus, cisplatin-induced encephalopathy is diagnosed using a multidisciplinary approach that includes clinical, radiological, and biological criteria. We must take into account the occurrence of neurological symptoms shortly following cisplatin infusion and rule out the other causes of encephalopathy in patients with cancer such as brain metastases, infectious causes, cerebral hemorrhage, and metabolic disorders (hyper/hypoglycemia, hyper/hypocalcemia, hyper/hyponatremia, azotemia) [ 5 , 8 ]. The improvement in symptomatology a few days after discontinuing therapy further supports the diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Management of Cisplatin-Induced Encephalopathy: A Case Report and Literature Review

Jebrouni,

Bailal,

Omari

et al. 2024

Cureus

View full text Add to dashboard Cite

Cisplatin is a cancer therapy drug commonly used. It is well-known for its antineoplastic properties, as well as for its numerous adverse effects, particularly its neurotoxicity. Symptoms associated with a central nervous system injury are unusual but can present a diagnostic challenge. Here, we report a case of a 62-year-old patient who was diagnosed with undifferentiated nasopharyngeal carcinoma. Cisplatin-based chemotherapy was administrated. Five days following the second cycle of treatment, the patient presented neurological disorders. A full biological workup and brain imaging were requested and revealed no abnormalities. The diagnosis of cisplatin encephalopathy was then suspected. Twenty days after cessation of cisplatin therapy, the neurological symptoms began to improve. Based on our case and a review of the literature, cisplatin-induced encephalopathy remains unusual. Its diagnosis is based on a combination of clinical, biological, and radiological criteria and requires the exclusion of other etiologies for neurological disorders in a patient being treated for cancer. Treatment is symptomatic and depends on stopping cisplatin therapy. These neurological adverse effects are often transitory and disappear without major repercussions.

show abstract

“…This complication can occur at the end of CDDP chemotherapy; despite the severity of this clinical syndrome, the majority of the patients make a full recovery (Steeghs et al, 2003; Zahir et al, 2012; Kabre and Kamble, 2016). Focal neurological deficits or a decreased level of consciousness, with or without seizures, has been described (Berman and Mann, 1980; Mead et al, 1982; Gorman et al, 1989; Brauers et al, 1997; Fuse-Nagase et al, 1997; Chue et al, 2009; Rohitashwa et al, 2016). Holman et al reported a case of SE associated with CDDP in a 54-year-old patient with recurrent cervical carcinoma without other underlying medical conditions (Holman et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-Related Encephalopathy With Super-Refractory Status Epilepticus in a Child With Osteosarcoma: A Case Report With a Review of Literature

et al. 2019

View full text Add to dashboard Cite

Osteosarcoma is the most frequent primary cancer of the bones, and a combination of primary chemotherapy, surgery, and adjuvant chemotherapy is its current treatment. In adults, some authors have reported problems with memory and concentration following chemotherapy, but in children, severe neurologic dysfunction has been rarely reported. This report describes a 13-year-old patient with primary high-grade nonmetastatic osteosarcoma of the tibia who developed encephalopathy with super-refractory status epilepticus related to chemotherapy. He received methotrexate (MTX) and cisplatin (CDDP)-containing polychemotherapy, and after the first course of drug administration, he developed fever, confusion, a state of psychomotor agitation, and super-refractory status epilepticus with normal laboratory and imaging findings. The causal relationship between the administration of the first polychemotherapy course and his neurological manifestations may be supported by the evaluation and exclusion of other causes. The administration of antiepileptic drugs and off-label atypical antipsychotics was necessary to treat his neurological complications and behavioral changes. This patient represents the first known example of super-refractory status epilepticus in a child treated with MTX and CDDP-containing chemotherapy. Physicians should be aware that encephalopathy and seizures are possible consequences of CDDP therapy when administered alone or in combination with other chemotherapeutic agents. Further studies are needed to better define this relationship in children.

show abstract

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix

Cited by 7 publications

References 6 publications

Identification of potential crucial genes and therapeutic targets for epilepsy

Identification of potential crucial genes and therapeutic targets for epilepsy

Management of Cisplatin-Induced Encephalopathy: A Case Report and Literature Review

Chemotherapy-Related Encephalopathy With Super-Refractory Status Epilepticus in a Child With Osteosarcoma: A Case Report With a Review of Literature

Contact Info

Product

Resources

About